KR20120107492A - 프로게스틴/에스트라디올 경피 젤 - Google Patents

프로게스틴/에스트라디올 경피 젤 Download PDF

Info

Publication number
KR20120107492A
KR20120107492A KR1020127018352A KR20127018352A KR20120107492A KR 20120107492 A KR20120107492 A KR 20120107492A KR 1020127018352 A KR1020127018352 A KR 1020127018352A KR 20127018352 A KR20127018352 A KR 20127018352A KR 20120107492 A KR20120107492 A KR 20120107492A
Authority
KR
South Korea
Prior art keywords
estradiol
progestin
transdermal
nes
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127018352A
Other languages
English (en)
Korean (ko)
Inventor
레진 시트룩-웨어
다리오 노르베르토 라몬 카라라
아르노 그르니에
Original Assignee
안타레스 파르마 아이피엘 에이쥐
더 파퓰레이션 카운실 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안타레스 파르마 아이피엘 에이쥐, 더 파퓰레이션 카운실 인코포레이티드 filed Critical 안타레스 파르마 아이피엘 에이쥐
Publication of KR20120107492A publication Critical patent/KR20120107492A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020127018352A 2009-12-17 2010-12-17 프로게스틴/에스트라디올 경피 젤 Ceased KR20120107492A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28751409P 2009-12-17 2009-12-17
US61/287,514 2009-12-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187019976A Division KR101928321B1 (ko) 2009-12-17 2010-12-17 프로게스틴/에스트라디올 경피 젤

Publications (1)

Publication Number Publication Date
KR20120107492A true KR20120107492A (ko) 2012-10-02

Family

ID=43640394

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127018352A Ceased KR20120107492A (ko) 2009-12-17 2010-12-17 프로게스틴/에스트라디올 경피 젤
KR1020187019976A Expired - Fee Related KR101928321B1 (ko) 2009-12-17 2010-12-17 프로게스틴/에스트라디올 경피 젤

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187019976A Expired - Fee Related KR101928321B1 (ko) 2009-12-17 2010-12-17 프로게스틴/에스트라디올 경피 젤

Country Status (14)

Country Link
US (1) US9682087B2 (enExample)
EP (1) EP2512486B1 (enExample)
JP (1) JP6082249B2 (enExample)
KR (2) KR20120107492A (enExample)
CN (1) CN102753180A (enExample)
AU (1) AU2010339867B2 (enExample)
BR (1) BR112012014059B1 (enExample)
CA (1) CA2782075C (enExample)
ES (1) ES2641613T3 (enExample)
IN (1) IN2012DN04867A (enExample)
MX (1) MX363536B (enExample)
NZ (1) NZ600907A (enExample)
WO (1) WO2011084668A1 (enExample)
ZA (1) ZA201204267B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN102657661A (zh) * 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2648470C2 (ru) * 2016-03-03 2018-03-26 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN117396195A (zh) * 2021-03-30 2024-01-12 晖致公司 具有低剂量雌激素的透皮系统及其制造和使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133077T2 (de) 1990-06-01 2002-11-07 The Population Council, New York Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
US5122382A (en) 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5198223A (en) * 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
JPH04342531A (ja) 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収製剤
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
WO2011049948A2 (en) * 2009-10-19 2011-04-28 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®

Also Published As

Publication number Publication date
CA2782075C (en) 2015-06-30
EP2512486A1 (en) 2012-10-24
KR20180084149A (ko) 2018-07-24
JP2013514984A (ja) 2013-05-02
IN2012DN04867A (enExample) 2015-09-25
BR112012014059A2 (pt) 2016-07-05
NZ600907A (en) 2013-11-29
KR101928321B1 (ko) 2018-12-12
ES2641613T3 (es) 2017-11-10
MX2012006755A (es) 2012-11-23
ZA201204267B (en) 2013-01-31
EP2512486B1 (en) 2017-06-28
MX363536B (es) 2019-03-27
WO2011084668A1 (en) 2011-07-14
AU2010339867B2 (en) 2014-07-24
AU2010339867A1 (en) 2012-07-19
JP6082249B2 (ja) 2017-02-15
BR112012014059B1 (pt) 2020-03-10
US9682087B2 (en) 2017-06-20
US20130045953A1 (en) 2013-02-21
CA2782075A1 (en) 2011-07-14
CN102753180A (zh) 2012-10-24
BR112012014059A8 (pt) 2017-12-26

Similar Documents

Publication Publication Date Title
KR101928321B1 (ko) 프로게스틴/에스트라디올 경피 젤
US8647665B2 (en) Methods of treating hot flashes with formulations for transdermal or transmucosal application
JP5441966B2 (ja) 活性薬の経皮又は経粘膜適用のための使用及び製剤
TWI564029B (zh) 睪固酮調配物
EP1482948B1 (en) Continuous sulfatase inhibiting progestogen hormone replacement therapy
Samsioe Transdermal hormone therapy: gels and patches
CN1972692A (zh) 治疗经前焦虑障碍的组合物和方法
US20040142914A1 (en) Extended transdermal contraceptive regimens
US20080220068A1 (en) Treatment and prevention of excessive scarring
EP2046310B1 (en) Treatment and prevention of excessive scarring
Sitruk-Ware et al. Patent: Nestorone®/estradiol transdermal gel
JP2025516643A (ja) プロゲスチン／テストステロン経皮ゲル剤
EP1891945A1 (en) Treatment and prevention of excessive scarring
MX2008013207A (es) Metodos para tratamiento de bochornos con formulaciones para aplicacion transdermica o transmucosa.
HK1108632A (en) Uses and formulations for transdermal or transmucosal application of active agents
HK1132453A (en) Methods of treating hot flashes with formulations for transdermal or transmucosal application

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120713

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151124

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170424

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170928

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170424

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170928

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170623

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20120718

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171129

Patent event code: PE09021S01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180621

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20171129

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171030

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170928

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170623

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170424

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20120718

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180712